AURANOFIN - Generic Drug Details

✉ Email this page to a colleague

What are the generic drug sources for auranofin and what is the scope of freedom to operate?

Auranofin is the generic ingredient in one branded drug marketed by Sebela Ireland Ltd and is included in one NDA. Additional information is available in the individual branded drug profile pages.

There are seven drug master file entries for auranofin. One supplier is listed for this compound.

Summary for AURANOFIN

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Drug Master File Entries:	7
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	34
Clinical Trials:	13
Patent Applications:	130
What excipients (inactive ingredients) are in AURANOFIN?	AURANOFIN excipients list
DailyMed Link:	AURANOFIN at DailyMed

Recent Clinical Trials for AURANOFIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Anticancer Fund, Belgium	Phase 1/Phase 2
University of Ulm	Phase 1/Phase 2
The Aurum Institute NPC	Phase 2

See all AURANOFIN clinical trials

Medical Subject Heading (MeSH) Categories for AURANOFIN

Antirheumatic Agents

Anatomical Therapeutic Chemical (ATC) Classes for AURANOFIN

M01CB	Gold preparations
M01C	SPECIFIC ANTIRHEUMATIC AGENTS
M01	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
M	Musculo-skeletal system

US Patents and Regulatory Information for AURANOFIN

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sebela Ireland Ltd	RIDAURA	auranofin	CAPSULE;ORAL	018689-001	May 24, 1985		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for AURANOFIN

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sebela Ireland Ltd	RIDAURA	auranofin	CAPSULE;ORAL	018689-001	May 24, 1985	⤷ Sign Up	⤷ Sign Up
Sebela Ireland Ltd	RIDAURA	auranofin	CAPSULE;ORAL	018689-001	May 24, 1985	⤷ Sign Up	⤷ Sign Up
Sebela Ireland Ltd	RIDAURA	auranofin	CAPSULE;ORAL	018689-001	May 24, 1985	⤷ Sign Up	⤷ Sign Up
Sebela Ireland Ltd	RIDAURA	auranofin	CAPSULE;ORAL	018689-001	May 24, 1985	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.